

## ***VCN Biosciences to present Two Investor Conferences in May 2019***

May 6, 2019 – VCN Biosciences, a clinical-stage company developing oncolytic immuno-oncology products today announced that Manel Cascallo, Chief Executive Officer, will present at the following upcoming investor conferences:

- BioEquity 2019; Monday, May 20, 15:45h in Barcelona (Spain)
- 5th Annual Immuno-Oncology BD&L and Investment Forum (during ASCO 2019 Meeting); Friday, May 31, 13:45h in Chicago (US)

### ***About VCN Biosciences***

VCN Biosciences is a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses. VCN candidates are designed to obtain clinical activity after systemic administration and are able to remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences lead product, VCN-01, is a oncolytic adenovirus with unique characteristics being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. For more information, please visit [HYPERLINK "http://www.vcnbiosciences.com"](http://www.vcnbiosciences.com)